BWH receives $140M grant from NIAID to support ongoing research led by AIDS Clinical Trial Group

Published on December 16, 2013 at 11:51 PM · No Comments

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded two seven-year grants to Brigham and Women's Hospital (BWH) to fund the AIDS Clinical Trial Group (ACTG) Network. The grants support the ACTG's Leadership and Operations Center (LOC) and Laboratory Center (LC). The funding totals $20 million annually or $140 million over seven years.

"The work accomplished by the ACTG over the last quarter century has had a profound impact on the wellbeing of persons living with HIV/AIDS, tuberculosis and viral hepatitis," said Daniel Kuritzkes, MD, chief of the Division of Infectious Diseases at BWH, principal investigator and chair of the ACTG.. "Results of ACTG trials have helped establish the paradigm for the management of HIV disease and form the basis of current treatment guidelines in the US and internationally. This progress has resulted in dramatic reductions in AIDS mortality across the globe. These accomplishments have been accelerated by an innovative alliance of academic, government and industry scientists, clinicians, regulatory agencies and community advocates. We are delighted that NIAID has provided us the opportunity to continue this important work over the next seven years."

The ACTG is an international consortium of clinical research sites conducting clinical trials in HIV-infected adults to test novel therapeutic interventions focused on HIV-associated inflammation and resulting end-organ disease, tuberculosis, viral hepatitis and HIV cure.

The continued funding underscores how Ed Perlmutter, 65, an ACTG study participant, feels about the importance of this work. Perlmutter joined the ACTG in 2006 when he was diagnosed with HIV.

"The first study I participated in helped to determine what antiretroviral drugs worked best in my patient population. I knew, after that study ended, that I directly helped other people with HIV determine what drugs would be best for them," he explained.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment